logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharma up on cancer trial positive as it raises €3.12mln to advance development programmes

The AIM-listed clinical-stage biopharmaceutical company said 864,164 shares were placed at a price of 60.0p each with institutional investors after an accelerated bookbuild process

Immunotherapy
Dr Markku Jalkanen, Faron’s CEO commented: "This provides Faron with the opportunity to further two significant clinical programme"

Faron Pharmaceuticals Oy (LON:FARN) shares rose on Tuesday as some positive progress from a cancer treatment trial was released as the firm raised up to €3.12mln (£2.67mln) before expenses via a placing and share subscription to advance its development programmes and provide working capital into the third-quarter of 2019.

The AIM-listed clinical-stage biopharmaceutical company said 864,164 shares were placed at a price of 60.0p each with institutional investors after an accelerated bookbuild process conducted by broker Panmure Gordon. In late afternoon trading, Faron Pharma shares were holding above that level, 3.3% higher at 63p.

READ: Faron Pharma chief executive says Clevegen results suggest it can be a new tool against cancer

In addition, the group said that 3,584,461 shares will be issued at an equivalent euro Issue price of 70.2 cents per share under a subscription to certain directors and a member of Faron’s Scientific Advisory Board.

The company said the fundraising’s proceeds will be used to advance the phase I/II MATINS trial for its immunotherapy cancer treatment Clevegen.

The group revealed that the MATINS study has now recruited four subjects with no safety concerns at 0.3 and 1.0 mg/kg dosing.

Faron Pharma pointed out that it has now also received a tumour imaging report on patient number two, a colorectal cancer sufferer, indicating a partial response after having previously been treated with six different anti-cancer drugs, which had all failed.

It added that, as the trial is an open-label study, the company receives new information on the progress of dose escalation and safety as the trial progresses and will announce material updates when appropriate.

The firm said the funds will also be used to further the development of lung inflammation treatment, Traumakine through the design and preparation of a global Phase III clinical trial, CALIBER, as well as for advancing partnering discussions in respect of both Traumakine and Clevegen.

Dr Markku Jalkanen, Faron’s CEO commented: "This provides Faron with the opportunity to further two significant clinical programmes, which aim to help people with serious life-threatening conditions like organ damage and cancer.

“I am also extremely happy with the level of support indicated by existing shareholders, Company directors and employees in this financing round. We are very excited to have two clinical programmes to progress further towards effective treatments."

 -- Adds placing result, updates share price --

Quick facts: Faron Pharmaceuticals Ltd

Price: 250 GBX

AIM:FARN
Market: AIM
Market Cap: £108.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharmaceuticals makes 'groundbreaking discovery' in its MATINS trial

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen. He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the...

11 hours, 5 minutes ago

RNS

Price Monitoring Extension

8 hours, 7 minutes ago

Matins Trial Update

1 day, 15 hours ago

Second Price Monitoring Extn

1 week, 3 days ago

Price Monitoring Extension

1 week, 3 days ago

Second Price Monitoring Extn

1 week, 6 days ago

Price Monitoring Extension

1 week, 6 days ago

LIQUIDITY PROVIDING AGREEMENT

1 week, 6 days ago

2 min read